Of note, we also found that CD8 T-cells in the tumour parenchyma and stroma of the immune-enriched immunotype had significantly upregulated PD-1 and other inhibitory receptors (figure 3G) and interacted with PD-L1+APCs and macrophages (online supplemental figure 4A), suggesting that they could be targeted by current ICI therapies. Here, CD8A is linked to neoplasm.